Innate Immune Mechanisms of Non-infectious Lung Inflammation
Innate Immune Mechanisms of Non-infectious Lung Inflammation
批准号:
10213598
负责人:
Paul Wesley Noble
金额:
$52.51万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-01 至 2023-07-31
关键词:
AchievementAdultAlveolarAwardCD44 AntigensCD44 geneCell AgingCell membraneCell surfaceCellsDataDiseaseEpigenetic ProcessEpithelial CellsExtracellular MatrixFailureFibroblastsFibrosisFundingGene TargetingGeneticGlycosaminoglycansGoalsHAS2 geneHumanHyaluronanImmunologic ReceptorsImpairmentIn VitroInflammationInterleukin-6LabelLaboratoriesLeadLungLung InflammationLung diseasesMediator of activation proteinMolecularMusPatientsPreventionPulmonary FibrosisReceptor SignalingRegulationRoleSignal TransductionTLR4 geneTestingTimeTissuesToll-like receptorsalveolar epitheliumbasecytokineeffective therapyepithelial repairepithelial stem cellidiopathic pulmonary fibrosisin vivoinjury and repairinnate immune mechanismsinterstitiallung injurylung repairmacrophagemouse modelnovel strategiespreventprogramsreceptorself-renewalstem cell divisionstem cellstissue repairtool
中文摘要
摘要
控制干细胞更新和组织纤维化的分子机制仍然不完全
明白该计划是我们不断努力阐明细胞外基质成分的作用,
先天免疫受体在调节肺损伤、炎症和纤维化中的作用。 特发性肺纤维化
(IPF)是一种致命的肺部疾病,部分原因是肺泡上皮修复不足,导致
过度的成纤维细胞活性。 我们的实验室在上一个创建时期已经产生了一系列的工作
显示糖胺聚糖透明质酸(HA)和先天性免疫受体TLR 4在肺泡上皮细胞表达,
上皮细胞和巨噬细胞在调节肺炎症和纤维化中具有重要作用,
非感染性肺损伤的背景下。HA由透明质酸合成酶2(HAS 2)在细胞膜上合成。
我们已经发现,在肺上皮细胞的细胞表面上表达的HA具有保护功能
对抗依赖于TLR 4的非感染性损伤。新的发现使我们形成了
这种更新的应用是先天免疫受体与内源性细胞外基质相互作用,
促进肺泡祖细胞更新。在过去的几年里,我们的团队已经开发出了国家级的
在非感染性肺损伤的情况下,靶向2型肺泡上皮细胞(AEC 2)的最新工具。
在该奖项的资助期间,我们发现缺乏TLR 4或靶向TLR 4的小鼠,
AEC 2中HAS 2的缺失对非慢性感染性肺损伤非常敏感,
间质纤维化从TLR 4缺陷或HAS 2靶向缺失的小鼠中分离的AEC 2显示,
自我更新能力降低。我们首次发现,先天免疫受体与基质
是肺干细胞更新和预防严重纤维化所必需的。 我们已经确定IL-16是一种
AEC 2以依赖于HA-β-TLR 4相互作用的方式释放的推定的细胞因子介体促进
干细胞更新和调节肺纤维化。 最重要的是,我们发现,
与健康供体肺相比,IPF患者肺的AEC 2减少。AEC 2来自
IPF肺显示相对于来自健康肺的细胞,细胞表面HA减少和更新能力受损。
肺 这些数据进一步支持IPF是AEC 2失败的疾病的概念,并且我们的小鼠模型
概括了人类肺纤维化疾病的关键方面。 根据我们的初步研究,
提出了细胞表面HA与其受体之间的相互作用是重要组成部分的假设
AEC 2祖细胞更新和肺修复的相互作用,这些相互作用的丧失导致严重的肺纤维化。在
在本研究中,我们将明确AEC 2中TLR 4、CD 44、NF-κ B B和HAS 2促进细胞凋亡的机制。
祖细胞更新和肺修复。实现此应用程序的目标将
这为肺部疾病的治疗提供了一种全新的方法。
英文摘要
Abstract
The molecular mechanisms that control stem cell renewal and tissue fibrosis remain incompletely
understood. This program is our continuous effort to elucidate the role of extracellular matrix components and
innate immune receptors in regulating lung injury, inflammation, and fibrosis. Idiopathic pulmonary fibrosis
(IPF) is a fatal lung disease resulting, in part, from inadequate alveolar epithelial repair leading to detonation of
excessive fibroblast activity. Our laboratory has generated a body of work during the last founding period
showing that glycosaminoglycan hyaluronan (HA) and innate immune receptor TLR4 expressed on alveolar
epithelial cells and macrophages have important roles in regulating lung inflammation and fibrosis in the
context of noninfectious lung injury. HA is synthesized at the cell membrane by hyaluronan synthase 2 (HAS2).
We have discovered that HA expressed on the cell surface of lung epithelial cells serves a protective function
against noninfectious insults that is dependent upon TLR4. The new findings that lead us to forms the basis for
this renewal application is that innate immune receptors interact with endogenous extracellular matrix to
promote alveolar progenitor cell renewal. During the past several years, our team has developed state-of-the-
art tools to target both Type 2 alveolar epithelial cells (AEC2s) in the context of noninfectious lung injury.
During the funding period of this award, we discovered that mice deficient in either TLR4 or with a targeted
deletion of HAS2 in AEC2s are enormously sensitive to non-infectious lung injury and develop fulminant
interstitial fibrosis. AEC2s isolated from mice deficient in either TLR4 or with a targeted deletion of HAS2 show
reduced self-renewal capacity. We show for the first time, that innate immune receptors interacting with matrix
are necessary for lung stem cell renewal and prevention of severe fibrosis. We have identified IL-6 as a
putative cytokine mediator released by AEC2s in a manner dependent on HA-TLR4 interactions promotes
stem cell renewal and modulates lung fibrosis. Most importantly, we have found that there is a significant
reduction of AEC2s from the lung of patients with IPF compared to the lung of healthy donors. AEC2s from the
IPF lungs showed reduced cell surface HA and impaired renewal capacity relative to the cells from healthy
lungs. These data further support the concept that IPF is a disease of AEC2 failure and our mouse model
recapitulates key aspects of the human lung fibrotic disease. Based on our preliminary studies, we have
generated the hypothesis that interactions between cell surface HA and its receptors are essential components
of AEC2 progenitor cell renewal and lung repair, and loss of these interactions results in severe lung fibrosis. In
this proposal, we will define the mechanisms by which TLR4, CD44, NF-kB, and HAS2 in AEC2s promote
progenitor cell renewal and lung repair in mouse and human. Achievement of the goals of this application will
result in a completely novel approach to the treatment of lung diseases.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
CD44 deficiency is associated with increased bacterial clearance but enhanced lung inflammation during Gram-negative pneumonia.
CD44 缺乏与细菌清除率增加有关,但革兰氏阴性肺炎期间肺部炎症增强。
DOI:
10.2353/ajpath.2010.100562
发表时间:
2010
期刊:
The American journal of pathology
影响因子:
--
作者:
[vanderWindt,GerritjeJW, Florquin,Sandrine, deVos,AlexF, van'tVeer,Cornelis, Queiroz,KarlaCS, Liang,Jiurong, Jiang,Dianhua, Noble,PaulW, vanderPoll,Tom]
通讯作者:
vanderPoll,Tom
Molecular Regulation of Progressive Pulmonary Fibrosis
-
批准号:10579263
-
项目类别:
-
资助金额:$84.75万
-
财政年份:2020
-
负责人:Paul Wesley Noble
-
依托单位:
Molecular Regulation of Progressive Pulmonary Fibrosis
-
批准号:9894657
-
项目类别:
-
资助金额:$84.75万
-
财政年份:2020
-
负责人:Paul Wesley Noble
-
依托单位:
Molecular Regulation of Progressive Pulmonary Fibrosis
-
批准号:10352422
-
项目类别:
-
资助金额:$84.75万
-
财政年份:2020
-
负责人:Paul Wesley Noble
-
依托单位:
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
-
批准号:10450041
-
项目类别:
-
资助金额:$51.0万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Host Factors in Regulation of Inflammatory and Fibroproliferative Lung Disease
-
批准号:8514063
-
项目类别:
-
资助金额:$183.02万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Administrative Core
-
批准号:10198008
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis and Chronic Allograft Dysfunction (CLAD)
-
批准号:10197999
-
项目类别:
-
资助金额:$236.83万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
-
批准号:10198011
-
项目类别:
-
资助金额:$51.0万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis and Chronic Allograft Dysfunction (CLAD)
-
批准号:10450037
-
项目类别:
-
资助金额:$236.83万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Administrative Core
-
批准号:10450038
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Hyaluronan in Pulmonary Fibrosis and Asthma
-
批准号:8403438
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Host Factors in Regulation of Inflammatory and Fibroproliferative Lung Disease
-
批准号:8680332
-
项目类别:
-
资助金额:$186.23万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
Host Factors in Regulation of Inflammatory and Fibroproliferative Lung Disease
-
批准号:8870406
-
项目类别:
-
资助金额:$184.96万
-
财政年份:2012
-
负责人:Paul Wesley Noble
-
依托单位:
MATRIX REGULATION OF FIBROPROLIFERATIVE LUNG DISEASE
-
批准号:7917410
-
项目类别:
-
资助金额:$44.84万
-
财政年份:2009
-
负责人:Paul Wesley Noble
-
依托单位:
Regulation of Pulmonary Fibrosis by CXCR3
-
批准号:7186704
-
项目类别:
-
资助金额:$36.94万
-
财政年份:2006
-
负责人:Paul Wesley Noble
-
依托单位:
Regulation of Pulmonary Fibrosis by CXCR3
-
批准号:7282288
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2006
-
负责人:Paul Wesley Noble
-
依托单位:
MATRIX REGULATION OF FIBROPROLIFERATIVE LUNG DISEASE
-
批准号:7231785
-
项目类别:
-
资助金额:$24.32万
-
财政年份:2006
-
负责人:Paul Wesley Noble
-
依托单位:
Regulation of Pulmonary Fibrosis by CXCR3
-
批准号:7365233
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2006
-
负责人:Paul Wesley Noble
-
依托单位:
Regulation of Pulmonary Fibrosis by CXCR3
-
批准号:7983785
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2005
-
负责人:Paul Wesley Noble
-
依托单位:
Regulation of Pulmonary Fibrosis by CXCR3
-
批准号:7019160
-
项目类别:
-
资助金额:$12.45万
-
财政年份:2005
-
负责人:Paul Wesley Noble
-
依托单位:
海外基金